Ameren, a St. Louis-based utility company, is presented as a strong dividend investment with a current yield of 2.78% and an annualized dividend of $3.00, up 5.6% year-over-year. The company has consistently increased dividends over the past 5 years with an average annual increase of 7.11%. With expected earnings growth of 7.36% for 2026 and a moderate payout ratio of 56%, Ameren is rated as a Hold (Zacks Rank #3), making it an attractive option for income investors seeking stable cash flow.
AEE
Ameren Corporation · NYSE
News
4 latestAmeren, a St. Louis-based utility company, is presented as a strong dividend investment with a current yield of 2.95% and annualized dividend of $3.00, up 5.6% year-over-year. The company has consistently increased dividends over the past 5 years with an average annual increase of 7.11%. With solid earnings growth projected at 7.36% for 2026 and a sustainable 56% payout ratio, Ameren is positioned as an attractive income investment, though it carries a Zacks Rank of #3 (Hold).
Ameren (AEE), a utility company in the electric power industry, is highlighted as a stock likely to beat upcoming earnings estimates. The company has demonstrated a strong earnings-beat streak with an average surprise of 7.02% over the last two quarters. With a positive Earnings ESP of +1.10% and a Zacks Rank #3 (Hold), analysts suggest another earnings beat is possible, as stocks with this combination historically beat consensus estimates nearly 70% of the time.
Ameren Corporation (AEE) is drawing attention from options traders due to high implied volatility in its December 18, 2026 $60 Call options, suggesting market expectations for significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Utility - Electric Power industry, with analyst consensus estimates slightly increasing from $2.25 to $2.27 per share over the last 30 days. Options traders may be positioning to sell premium and capture decay rather than betting on directional movement.
Headlines link to the publisher. Not investment advice.